2
may
Immusoft Granted Orphan Drug Designation for Treatment of Rare Childhood Disease
Immusoft Granted Orphan Drug Designation for Treatment of Rare Childhood Disease
U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to treat the first indication in the company’s pipeline, MPS I (Mucopolysaccharidosis type I).